BioLargo's PFAS Treatment Technology Meets EPA's Proposed New Drinking Water Standards - Seite 2
BioLargo's President and CEO Dennis P. Calvert commented, "For BioLargo, the timing of this news is perfect. Assuming these regulations go into effect as written, many municipalities will soon be required to install PFAS treatment systems. Our system is the practical, affordable, sustainable solution for all PFAS treatment, generating far less PFAS-laden solid waste than other options. Our team is also being recognized for their expertise on PFAS, with our Director of Commercialization Tonya Chandler being sought after as a speaker at PFAS-focused events many times over the past year."
He continued, "With our first customer for PFAS treatment already secured and underway - a large industrial site - we are eager to offer our PFAS solution to more municipal and industrial customers over the coming year. As a reminder, we don't just treat water contaminated with PFAS, we also take on the responsibility of handling their solid waste to make it simple for the customer."
What are PFAS?
Per- and polyfluoroalkyl substances (PFAS) are a group of harmful chemicals widely used in manufacturing and consumer products, known to contaminate drinking water sources around the world, and are
both biopersistent (meaning they remain in organisms indefinitely without breaking down), and are bioaccumulative (meaning that over time, they build up in ever increasing amounts in people,
wildlife, aquatic life, and the environment). Having been detected in the blood of more than 99% of tested Americans, they are linked to increased incidence of cancer, liver and kidney disease,
reproductive issues, immunodeficiencies, and hormonal disruptions.
Lesen Sie auch
About BioLargo, Inc.
BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and
wastewater treatment, control odor and VOCs, improve air quality, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product
offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.